Literature DB >> 29252655

Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.

Andrew Park1, Cara A Cipriano1, Kirk Hill1, Michael Kyriakos1, Douglas J McDonald1.   

Abstract

CASE: Giant cell tumor (GCT) of bone was first described almost 200 years ago, but the optimal treatment continues to evolve. We present a patient with a pelvic GCT who was treated with embolization, 20 months of denosumab therapy, and resection. Histologically, the tumor consisted of degenerated GCT, bone, and fibrous tissue. After 7 months, the patient was found to have osteosarcoma at the site of the initial lesion as well as pulmonary metastases.
CONCLUSION: The apparent malignant transformation of a GCT of bone treated initially with denosumab indicates that close follow-up is warranted.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 29252655     DOI: 10.2106/JBJS.CC.16.00024

Source DB:  PubMed          Journal:  JBJS Case Connect        ISSN: 2160-3251


  7 in total

1.  Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology.

Authors:  Kalevi Kairemo; Wei-Lien Wang; Vivek Subbiah
Journal:  BMJ Case Rep       Date:  2019-04-23

Review 2.  Malignant giant cell tumour of bone: a review of clinical, pathological and imaging features.

Authors:  Ismail Tahir; Vanghelita Andrei; Robin Pollock; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-09-25       Impact factor: 2.199

3.  Primary Bone Tumor of the Spine-An Evolving Field: What a General Spine Surgeon Should Know.

Authors:  Raphaële Charest-Morin; Charles G Fisher; Arjun Sahgal; Stefano Boriani; Ziya L Gokaslan; Aron Lazary; Jeremy Reynolds; Chetan Bettegowda; Laurence D Rhines; Nicolas Dea
Journal:  Global Spine J       Date:  2019-05-08

4.  Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.

Authors:  Marc Hasenfratz; Kevin Mellert; Ralf Marienfeld; Alexandra von Baer; Markus Schultheiss; P D Roitman; L A Aponte-Tinao; Burkhard Lehner; Peter Möller; Gunhild Mechtersheimer; Thomas F E Barth
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

5.  Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy.

Authors:  Eiji Nakata; Hotaka Kawai; Tomohiro Fujiwara; Toshiyuki Kunisada; Hirofumi Inoue; Mashu Futagawa; Haruyoshi Katayama; Takuto Itano; Toshifumi Ozaki
Journal:  Oncol Lett       Date:  2022-07-19       Impact factor: 3.111

6.  Premalignant Conditions of Bone.

Authors:  Michael D Eckhoff; Matthew E Wells; Osvaldo Padilla; Elizabeth M Polfer; Christopher J Castagno; Ahmed M Thabet; Shaimaa Elzamly; Harry L Wilson; Rajiv Rajani
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-10-13

7.  Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?

Authors:  Francesca Punzo; Chiara Tortora; Maura Argenziano; Daniela Di Pinto; Elvira Pota; Martina Di Martino; Alessandra Di Paola; Francesca Rossi
Journal:  Oncotarget       Date:  2020-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.